Abstract

Cancer is regarded as global burden and a serious health challenge. Its occurrences increased due to population aging and the prevalence of risk factors. This study investigated the eff ect of metformin and aspirin on two cell lines SR (diff use large B cell lymphoma) and NB4 (promyelocytic leukemia). The eff ect of metformin as monotherapy on SR was 28.43% viable, while on NB4, only 44.4% were viable. However, the eff ect of aspirin on SR and NB4 cell lines were decreased; the percentage of cell viability were 27.2 and 41.2%, respectively. In conclusion, there is signifi cant eff ect of metformin and aspirin on SR cell line and only mild eff ect on NB4. These may be useful drugs in old diabetic patients with diff use large B cell lymphoma that may reduce the chemotherapy dose

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.